Brokerages expect that Teladoc, Inc. (NYSE:TDOC) will report ($0.52) earnings per share (EPS) for the current quarter, Zacks reports. Seven analysts have made estimates for Teladoc’s earnings. The lowest EPS estimate is ($0.57) and the highest is ($0.19). Teladoc reported earnings per share of ($0.33) in the same quarter last year, which would suggest a negative year-over-year growth rate of 57.6%. The firm is expected to announce its next earnings report on Thursday, October 26th.

On average, analysts expect that Teladoc will report full-year earnings of ($1.46) per share for the current fiscal year, with EPS estimates ranging from ($1.63) to ($0.85). For the next year, analysts forecast that the firm will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.72) to ($0.66). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Teladoc.

Teladoc (NYSE:TDOC) last posted its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.02. The firm had revenue of $44.60 million for the quarter, compared to the consensus estimate of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The business’s revenue was up 68.3% on a year-over-year basis. During the same period last year, the company posted ($0.38) EPS.

Several equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a report on Thursday, May 11th. Piper Jaffray Companies reiterated a “buy” rating and issued a $42.00 price target on shares of Teladoc in a report on Friday, July 28th. Chardan Capital increased their price target on shares of Teladoc from $30.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, June 20th. Craig Hallum downgraded shares of Teladoc from a “buy” rating to a “hold” rating and increased their price target for the stock from $28.00 to $32.00 in a report on Friday, May 12th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $27.00 price target on shares of Teladoc in a report on Monday, June 19th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $35.55.

TRADEMARK VIOLATION NOTICE: “Analysts Expect Teladoc, Inc. (TDOC) Will Announce Earnings of -$0.52 Per Share” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/21/analysts-expect-teladoc-inc-tdoc-will-announce-earnings-of-0-52-per-share.html.

Teladoc (NYSE:TDOC) traded down 1.53% during mid-day trading on Monday, reaching $29.05. 260,280 shares of the company were exchanged. The stock has a 50 day moving average of $33.13 and a 200-day moving average of $27.90. The stock’s market capitalization is $1.65 billion. Teladoc has a one year low of $14.00 and a one year high of $36.90.

In other news, insider Adam C. Vandervoort sold 53,806 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the sale, the insider now owns 33,008 shares of the company’s stock, valued at approximately $1,020,607.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jason N. Gorevic sold 5,600 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $29.57, for a total transaction of $165,592.00. Following the sale, the chief executive officer now directly owns 823,861 shares in the company, valued at approximately $24,361,569.77. The disclosure for this sale can be found here. Insiders have sold a total of 107,186 shares of company stock worth $3,352,950 in the last ninety days. Corporate insiders own 5.94% of the company’s stock.

Large investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its stake in shares of Teladoc by 134.2% in the second quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock worth $164,000 after buying an additional 2,707 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Teladoc by 101.9% in the second quarter. California State Teachers Retirement System now owns 95,321 shares of the health services provider’s stock worth $3,308,000 after buying an additional 48,112 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Teladoc during the second quarter worth approximately $202,000. The Manufacturers Life Insurance Company boosted its stake in shares of Teladoc by 132.9% in the second quarter. The Manufacturers Life Insurance Company now owns 41,270 shares of the health services provider’s stock worth $1,432,000 after buying an additional 23,553 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Teladoc during the second quarter worth approximately $2,316,000. 94.51% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Get a free copy of the Zacks research report on Teladoc (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.